Abstract 31P
Background
Incidence rates of breast cancer have been increasing in every country with significant higher proportion of cancer-related mortality particularly in low- and middle-income countries including in Indonesia. Developing novel biomarker is an emerging field in the breast cancer study. Application of a promising minimally-invasive biomarker, circulating microRNA, for additional improvement of diagnosis and therapeutic monitoring in breast cancer is not fully understood.
Methods
We analysed expression of circulating miR-155 in 102 breast cancer patients at diagnosis and after treatment as well as 15 healthy women. Total RNA was extracted from patient’s plasma and microRNA expression was measured using quantitative reverse transcription polymerase chain reaction (qRT-PCR). The expression levels of circulating miR-155 were compared according to the effect of treatment, clinicopathological variables, and progression-free survival.
Results
In comparison to the healthy women, expression of circulating miR-155 levels were significantly higher (medians were 18.49±19 and 1.28±0.18, respectively; p < 0.0001). The expression levels of miR-155 were significantly reduced after patients completed surgery and chemotherapy (medians were 18.49±19 at diagnosis and 1.32±0.22 after treatment, respectively; p < 0.0001). Patients older than 40 years old expressed higher circulating miR-155 than those younger than 40 years-old (medians were 28.92±22 and 4.19±2.49, respectively; p < 0.0001). No significant different miR-155 expression levels at diagnosis were observed across tumor grades, sizes, subtypes, and clinical stages. Although patients with circulating miR-155 upregulation have longer progression-free survivals, the difference was not statistically significant compared to those without upregulation. (median survivals were 55 vs 43 weeks and Mantel-Cox test p = 0.7).
Conclusions
Expression of circulating miR-155 expression was significantly elevated in breast cancer patients and was decreased after treatment. Therefore, circulating miR-155 was potentially applicable as diagnostic and therapeutic monitoring marker in breast cancer.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Universities Gadjah Mada.
Funding
The Ministry of Research and Higher Education - Republic of Indonesia (PTUPT 1818/UNI/DITLIT/LT/2018 and PPUPT 1987/UNI/DITLIT/LT/2018).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
238P - Laparoscopic cytoreduction in low disease burden, advanced-stage ovarian cancers: Experience from a tertiary cancer center
Presenter: Vikas Gupta
Session: Poster display session
Resources:
Abstract
239P - Impact of counseling on patient reported sexual adjustment following chemoradiation and brachytherapy for cervical cancer
Presenter: Vibhay Pareek
Session: Poster display session
Resources:
Abstract
240P - Morbidity and mortality of cervical cancer in the Republic of Kazakhstan
Presenter: Almagul Zhabagina
Session: Poster display session
Resources:
Abstract
241P - Impact of genomic alterations and HPV genotypes on clinical outcomes of Japanese patients with locally advanced cervical cancer
Presenter: Ikumi Kuno
Session: Poster display session
Resources:
Abstract
242P - Impact of combined interstitial and intracavitary brachytherapy in locally advanced cervical cancer: A survival and toxicity profile assessment
Presenter: Vibhay Pareek
Session: Poster display session
Resources:
Abstract
243P - Cervical cancer screening in sub-urban area of Banten and factor associated with uptake of screening
Presenter: Prio Wibisono
Session: Poster display session
Resources:
Abstract
245P - Factors influencing adherence to cryotherapy following positive VIA result as cervical cancer prevention in Temanggung, Central Java, Indonesia
Presenter: Herindita Puspitaningtyas
Session: Poster display session
Resources:
Abstract
246P - The main of reasons of advanced stage cervical cancer in Uzbekistan
Presenter: Zakhirova Nargiza
Session: Poster display session
Resources:
Abstract
247P - Role of ADC values in assessing response after chemoradiotherapy in cervix cancer and in identifying residual disease
Presenter: Venkata Pradeep Babu Koyyala
Session: Poster display session
Resources:
Abstract
248P - Retrospective review of metastatic carcinoma of cervix from a tertiary cancer institute of south India
Presenter: Arkoprovo Halder
Session: Poster display session
Resources:
Abstract